Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results.

AJR Am J Roentgenol

Department of Radiology, Division of Angiography and Interventional Radiology, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

Published: May 2003

Objective: The purpose of our study was to assess the results of hepatic artery embolization using N-butyl-2-cyanoacrylate and ethiodized oil for the treatment of small-bowel neuroendocrine metastases to the liver as part of a multimodality protocol for the treatment of liver metastases from neuroendocrine small-bowel tumors.

Materials And Methods: Twenty-three patients underwent permanent embolization of the hepatic artery using cyanoacrylate and Lipiodol for treatment of liver metastases after radical resection of small-bowel neuroendocrine tumors. All patients received additional treatment including somatostatin, and most patients received interferon as well. Cumulative survival rates were estimated using the Kaplan-Meier method.

Results: Overall, 75 embolizations (range, 1-10; mean, 3.3) were performed. Median survival time was 69 months, and the estimated cumulative survival rates reached 95.7% and 65.4% for 1 and 5 years, respectively. Two deaths (8.7%) occurred within 1 month of treatment, and one patient experienced a vascular complication at the time of embolization.

Conclusion: Permanent embolization of hepatic arteries as part of a multimodality treatment protocol is beneficial in long-term follow-up for patients with metastasized small-bowel neuroendocrine tumors. The use of cyanoacrylate as an embolic agent is safe and effective.

Download full-text PDF

Source
http://dx.doi.org/10.2214/ajr.180.5.1801379DOI Listing

Publication Analysis

Top Keywords

small-bowel neuroendocrine
12
neuroendocrine metastases
8
metastases liver
8
cyanoacrylate lipiodol
8
hepatic artery
8
treatment liver
8
liver metastases
8
permanent embolization
8
embolization hepatic
8
neuroendocrine tumors
8

Similar Publications

Small intestine neuroendocrine tumours (SI-NETs) are often diagnosed late with a UK median of 3 years and high misdiagnosis rates. Previous studies, largely based on patient surveys, offer little data on improving diagnosis. In 2017, the South Wales NET service underwent a nationally commissioned, systematic transformation, aiming to improve diagnosis through the development of a gastroenterology and surgical referral network, and education of these specialities.

View Article and Find Full Text PDF

Purpose: To evaluate organ-specific response to [Lu]DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in patients with small intestine neuroendocrine tumor (SiNET) through [Ga]DOTATOC PET/CT, and to analyze tumor uptake and functional volume variations at different metastatic sites in relation to disease progression during clinical follow-up after treatment.

Methods: A retrospective analysis was conducted on 33 metastatic patients. PET/CT were performed pre-treatment (PET0), mid-treatment after two PRRT cycles (PET2), and post-treatment (PET4).

View Article and Find Full Text PDF

The ileocecal valve in transabdominal ultrasound. Part 2: Pathological lesions.

J Ultrason

December 2024

Department of Diagnostic Imaging and Interventional Radiology, Pomeranian Medical University, Szczecin, Poland.

The aim of this paper is to present our experience in transabdominal ultrasonography of ileocecal valve lesions. The ileocecal valve, located in the central part of the ileocecal bowel segment, is rarely the primary site of disease processes. It is usually involved by pathologies in adjacent bowel segments.

View Article and Find Full Text PDF

Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms.

Sci Rep

December 2024

Division of Vascular and Interventional Radiology, Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland, Baltimore, USA.

To investigate incidence, treatment patterns and outcomes of gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) in the United States. The 2019 National Cancer Database was searched for adult GEP-NEN patients. Main outcomes included overall and site-specific incidence, treatment patterns, and overall survival (OS).

View Article and Find Full Text PDF

Background: Numerous studies have indicated that the temozolomide and capecitabine regimen (TEMCAP) exhibits a certain level of efficacy in treating advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET). However, published data from Peru are limited. We hypothesize that this regimen could be a viable therapeutic option for advanced GEP-NET in the Peruvian population.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!